Clinical trials: Vascular Thrombosis
Venous Thromboembolism, Cancer
Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy
The primary objective was to compare the efficacy of once daily subcutaneous injections of Semuloparin sodium (AVE5026) with placebo in the prevention of venous thromboembolism [VTE] in cancer patients at high risk for VTE and…
- Trial name
- SAVE-ONCO (NCT00694382)
- Testing
- Semuloparin sodium
- Where
- 411 sites in United States, Argentina and 47 more
- Volunteers
- 3,212 people
- Sponsor
- Sanofi
IPMN, Pancreatic, Pancreatic Cancer, Resected
Venous Resection in Patients Undergoing Pancreatic Surgery
Pancreatic surgery is the only treatment in the multimodality approach to pancreatic cancer sine qua non long-term survival cannot be achieved.
- Conditions
- IPMN, Pancreatic, Pancreatic Cancer, Resected, Pancreatic Cancer Borderline, Chronic Pancreatitis
- Trial name
- VENUS (NCT07621029)
- Where
- 2 sites in Netherlands, Sweden
- Volunteers
- 1,000 people
- Sponsor
- Sahlgrenska University Hospital
Coronary Heart Disease
Clopidogrel Response Evaluation and AnTi-Platelet InterVEntion in High Thrombotic Risk PCI Patients
To identify the high-risk patients who might have in-stent thrombosis after PCI with thromboelastography and to head-to-head compare two intensified antiplatelet therapeutic strategies of double-dosage Clopidogrel and triple…
- Trial name
- CREATIVE (NCT01779401)
- Testing
- Clopidogrel 75mg, Clopidogrel 150mg, Aspirin 100mg
- Where
- 2 sites in China
- Volunteers
- 1,078 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Hepatocellular Carcinoma
The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) Who Underwent Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
To compare the impact on survival of neo-adjuvant TAI for patients with HCC and PVTT who underwent hepatectomy.
- Trial name
- NCT03368651
- Testing
- TAI
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Sun Yat-sen University
Peripheral ICC
PICC Asymptomatic Thrombosis Study: A Pilot Study
The study purpose is to perform a preliminary, comparative evaluation of the Hydrophilic Biomaterial technology to confirm the performance of the catheter, by using UltraSound technology in-vivo.
- Trial name
- NCT04920929
- Testing
- Hydrophilic Biomaterial, Thermoplastic Polyurethane
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Access Vascular Inc
Embolism, Paradoxical, Heart Septal Defects, Atrial
PC-Trial: Patent Foramen Ovale and Cryptogenic Embolism
The purpose of this study is to compare two treatments strategies to prevent further attacks in patients who have suffered an stroke or occlusion of a major artery with no obvious reason other than a persistent small opening…
- Trial name
- NCT00166257
- Testing
- Percutaneous closure of patent foramen ovale, Medical antitrhombotic treatment
- Where
- 6 sites in Australia, Austria and 2 more
- Volunteers
- 414 people
- Sponsor
- Foundation for Cardiovascular Research, Zurich
Coagulation and Hemorrhagic Disorders, Extracorporeal Membrane Oxygenation Complication
Coagulation Monitoring in Patients on Extracorporeal Membrane Oxygenation (Observational Study)
Coagulation disorders are on top of the list of extracorporeal-membrane oxygenation (ECMO) complications. They contribute significantly to morbidity and mortality of ECMO patients.
- Trial name
- NCT03642912
- Where
- Germany
- Volunteers
- 35 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Cardiac Death, Myocardial Infarction
Leaders Free III: BioFreedom™ Clinical Trial
A study evaluating the safety and efficacy of the BioFreedom™ Biolimus A9™ coated Cobalt Chromium coronary stent system in patients at high risk of bleeding
- Conditions
- Cardiac Death, Myocardial Infarction, Stent Thrombosis, Bleeding
- Trial name
- NCT03118895
- Testing
- BioFreedom™ BA9™ drug-coated stent
- Where
- 2 sites in France, Switzerland
- Volunteers
- 404 people
- Sponsor
- Biosensors Europe SA
Deep Vein Thrombosis
Microplasmin Administered Via the Trellis-8 Infusion System for Treatment of Acute Iliofemoral DVT
A single centre, single-arm study to evaluate safety and efficacy of microplasmin administration via the Trellis-8 Infusion System in patients with acute iliofemoral DVT
- Trial name
- MAX-DVT (NCT00428129)
- Testing
- microplasmin
- Where
- Ireland
- Volunteers
- 6 people
- Sponsor
- ThromboGenics
COPD Exacerbation, PTE - Pulmonary Thromboembolism
The Appropriate Anticoagulation Duration for Chronic Obstructive Pulmonary Disease With Pulmonary Thromboembolism
Anticoagulation is the most important treatment for pulmonary thromboembolism (PTE). The thromboembolism risk is especially high in patients with chronic obstructive pulmonary disease (COPD) exacerbations.
- Trial name
- NCT03185845
- Testing
- Warfarin
- Where
- China
- Volunteers
- 392 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Myocardial Infarction
Anti-inflammatory Effects of Intracoronary and Intravenous Abciximab Administration During Primary Percutaneous Coronary Intervention
Intracoronary abciximab administration during primary percutaneous coronary intervention (pPCI) could offer clinical advantages over the intravenous route.
- Trial name
- NCT01757457
- Testing
- Intracoronary administration of an abciximab bolus during primary PCI, Intravenous administration of an abciximab bolus during primary PCI
- Where
- Italy
- Volunteers
- 89 people
- Sponsor
- Azienda Ospedaliero Universitaria Maggiore della Carita
Raynaud Disease, Raynaud Disease Secondary to Scleroderma
Lab Study of MQX-503 in Treatment of Raynaud's
The purpose of this study is to determine, in comparison to a placebo control, the response to two dosage strengths of a topical gel formulation of nitroglycerin, MQX-303, in the determination of finger blood flow and skin…
- Conditions
- Raynaud Disease, Raynaud Disease Secondary to Scleroderma, Raynaud Secondary to Other Autoimmune Disease
- Trial name
- NCT00253331
- Testing
- topical organogel with nitroglycerin
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- MediQuest Therapeutics
Venous Thromboembolism
A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty
The objective of this study is to assess the efficacy and safety of DU-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective total knee arthroplasty.
- Trial name
- NCT01181102
- Testing
- edoxaban, enoxaparin sodium
- Where
- 3 sites in Japan, Taiwan
- Volunteers
- 716 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Thrombosis
Sickle Cell Trait and the Risk of Venous Thromboembolism
The purpose of this trial is to investigate D-Dimer levels, a surrogate marker of venous thromboembolism, in pregnant/postpartum white women as compared to pregnant/postpartum black women, and pregnant/postpartum women with…
- Trial name
- SCT&DVT (NCT01148940)
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine
Endocarditis, Thrombosis
Assessment of Radiolabeled rhAnnexin V-128 in Infective Endocarditis
Intraluminal thrombi adherent to cardiac valves or atria share a common pathophysiology involving the aggregation of activated platelets with phosphatidylserine (PS) expression on the outer layer of the thrombus.
- Trial name
- AnnIE (NCT02459613)
- Testing
- 99mTc-Annexin V-128 SPECT
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Congenital Antithrombin Deficiency
A Study of KW-3357 in Congenital Antithrombin Deficiency
The aim of this study is to determine the pharmacokinetics, safety and tolerability of KW-3357 in asymptomatic subjects with congenital antithrombin deficiency.
- Trial name
- NCT00938288
- Testing
- KW-3357
- Where
- 8 sites in Germany, Sweden and 1 more
- Volunteers
- 16 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Neoplasm Metastasis, Blood Coagulation Disorder With Shortened Coagulation Time (Disorder)
Application of a New Type of Whole Blood Coagulation Time Measurement in Evaluating the Hypercoagulable State of Malignant Tumors
Malignant tumors are closely related to deep vein thrombosis, Pulmonary embolism and other diseases. Tumor patients usually have a hypercoagulable state (HCS) in their blood, and the proportion of thrombosis caused by HCS is more…
- Conditions
- Neoplasm Metastasis, Blood Coagulation Disorder With Shortened Coagulation Time (Disorder), Venous Thromboembolism
- Trial name
- GCTHCM (NCT05939960)
- Testing
- CGT test
- Where
- China
- Volunteers
- 354 people
- Sponsor
- Tianjin Medical University General Hospital
Diabetic Retinopathy, Retinal Vein Occlusion
Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph
Blindness can be caused by many ocular diseases, such as diabetic retinopathy, retinal vein occlusion, age-related macular degeneration, pathologic myopia and glaucoma.
- Conditions
- Diabetic Retinopathy, Retinal Vein Occlusion, Retinal Artery Occlusion, Central Serous Chorioretinopathy
- Trial name
- NCT04723160
- Testing
- Software assisted imaging diagnosis
- Where
- 5 sites in China
- Volunteers
- 748 people, healthy volunteers welcome
- Sponsor
- Visionary Intelligence Ltd.
Venous Thrombosis, Pulmonary Embolism
Deep Venous Thrombosis After Hepatobiliopancreatic Surgery
To investigate the incidence of pre- and early postoperative deep venous thrombosis in patients undergoing hepatobiliopancreatic surgery, as well as potential corresponding risk factors with special attention to circulating tumor…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Hepatectomy, Pancreatectomy
- Trial name
- POPLITEA (NCT02649023)
- Where
- Germany
- Volunteers
- 76 people
- Sponsor
- Technische Universität Dresden
Retinal Vein Occlusion
Open Label Study to Assess the Efficacy and Safety of AKB-9778 in Subjects With Macular Edema Due to RVO
Phase 2a open-label study to assess the efficacy and safety of subcutaneous 15mg AKB-9778 administered twice daily for 84 days in subjects with macular edema due to RVO.
- Trial name
- NCT02387788
- Testing
- AKB-9778
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Aerpio Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.